K0024
KRAS Mutation Analysis: Exons 2, 3, 4
Number of Tests | 3 |
Test Included | Exon 2, Exon 3, Exon 4 |
Test Details: The KRAS mutation, which has been associated with several human cancers including lung adenocarcinomas, pancreatic cancers, gastric cancers, biliary cancers and colorectal cancers, is often an early event in tumorigenesis. The mutations of clinical significance are commonly observed in Exon 2 codons 12/ 13, Exon 3-codon 61 and Exon 4-codon 117/146 and are frequent in colorectal carcinomas. The impact of KRAS mutation on the efficacy of therapies that target the epidermal growth factor (EGFR) is aimed at identifying the best possible treatments.
![](assets/img/diagnleftimg.png)
Category
Molecular Genetics
Pre-test Information
Minimum of 20% (as assessed by the pathologist) tumor tissue should be available in each FFPE block/slide. Clinical details and histopathology reports mandatory.
Report Delivery
6 working days
Gender
All
Organ
Multi-Organ
KRAS Mutation Analysis: Exons 2, 3, 4
8800
Most Searched Diagnostic Tests